Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$399.7MCash on Hand
77.4mo Cash Runway
Follow PRGO by emailGet an email when PRGO pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about PRGO, unsubscribe in one click. Privacy
🧪 Trial & FDA Catalysts
May 2026 · N/A · Upcoming Trial · Comparative Study for the Evaluation of a New Medical Device Shampoo on the Treatment of H Registry primary completion date, not a results date
Apr 2021 · N/A · Results Expected · DBRPC Study to Evaluate the Efficacy and Safety of IQP-AE-103 in Overweight and Moderately Registry primary completion date, not a results date
Jul 2016 · N/A · Results Expected · Formula for Children With Cow's Milk Allergy Registry primary completion date, not a results date
Apr 2016 · Phase 3 · Results Expected · A Multicenter Study of Pseudoephedrine for the Temporary Relief of Nasal Congestion in Chi Registry primary completion date, not a results date
Mar 2013 · N/A · Results Expected · Growth and Safety of a Low Lactose Milk-Based Infant Formula Registry primary completion date, not a results date
Dec 2008 · N/A · Results Expected · Effects on Growth of an Extensively Hydrolyzed Formula Fed to Term Registry primary completion date, not a results date
Also used in these trials (approved or third-party drugs, not PRGO's own candidates): Pseudoephedrine Hydrochloride, Famotidine, Ibuprofen, Naproxen.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
PRGO holds $399.7M in cash and short-term investments (as of Jun 27, 2026) and burns about $15.5M/quarter from operations,
an estimated runway of 77.4 months at that rate (BioRadar estimate, not company guidance).
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for PRGO and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.